A carregar...
Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma
BACKGROUND: Tivozanib is a potent and selective tyrosine kinase inhibitor of vascular endothelial growth factor receptors (VEGFR)-1, −2 and −3, with a long half-life. Tivozanib has demonstrated clinical activity and acceptable tolerability in renal cell carcinoma (RCC). This phase Ib study determine...
Na minha lista:
| Publicado no: | Eur J Cancer |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2013
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4666006/ https://ncbi.nlm.nih.gov/pubmed/23726267 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejca.2013.04.019 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|